Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:26 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
NCT03361800 · UNC Lineberger Comprehensive Cancer Center · EARLY_PHASE1 · terminated · last registry update 2024-03-25 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding withdrawn.” | – | Registry record, UNC Lineberger Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-09-14Results posted on the registry: Syndax Pharmaceuticals, Entinostat + Atezolizumab (NCT02708680)
- 2023-08-31Results posted on the registry: University of California, San Francisco, Pembrolizumab + Tamoxifen (NCT04190056)
- 2023-08-31Also stopped (terminated): University of California, San Francisco, Pembrolizumab + Tamoxifen (NCT04190056)
- 2023-05-18Also stopped (withdrawn): Dana-Farber Cancer Institute, Implantable Microdevice (IMD) (NCT05774886)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision